Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Bayer Gets Swift Review for Kerendia in Type 1 Diabetes

The application is backed by Phase III data showing KERENDIA cut urine albumin-to-creatinine ratio over six months and could become the first MRA for this group.

Summary by Pharmaphorum
FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

4 Articles

PharmaphorumPharmaphorum
Center

Bayer gets swift review for Kerendia in type 1 diabetes

FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

Read Full Article
Rutland HeraldRutland Herald
+2 Reposted by 2 other sources
Center

Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--May 21, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news on Thursday, May 21, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Drought icon

Drought

New Jersey icon

New Jersey

Extreme Weather and Disasters icon

Extreme Weather and Disasters

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal